Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Benitec Biopharma (BNTC) Gross Profit (2019 - 2024)

Benitec Biopharma has reported Gross Profit over the past 6 years, most recently at -$3000.0 for Q1 2024.

  • Quarterly results put Gross Profit at -$3000.0 for Q1 2024, down 105.56% from a year ago — trailing twelve months through Dec 2024 was -$3000.0 (up 93.48% YoY), and the annual figure for FY2024 was -$108000.0, down 244.0%.
  • Gross Profit reached -$3000.0 in Q1 2024 per BNTC's latest filing, down from -$1000.0 in the prior quarter.
  • Across five years, Gross Profit topped out at $54000.0 in Q1 2023 and bottomed at -$106000.0 in Q3 2023.
  • Median Gross Profit over the past 5 years was -$1000.0 (2023), compared with a mean of -$5266.7.
  • The largest annual shift saw Gross Profit plummeted 1228.57% in 2020 before it surged 900.0% in 2022.
  • Over 5 years, Gross Profit stood at -$18000.0 in 2020, then surged by 238.89% to $25000.0 in 2021, then plummeted by 44.0% to $14000.0 in 2022, then plummeted by 107.14% to -$1000.0 in 2023, then plummeted by 200.0% to -$3000.0 in 2024.
  • Business Quant data shows Gross Profit for BNTC at -$3000.0 in Q1 2024, -$1000.0 in Q4 2023, and -$106000.0 in Q3 2023.